Diagnosed With Bladder Cancer After Actos? Call the Drug Litigation Attorneys at Eberstein & Witherite
DALLAS, Feb. 2, 2012 /PRNewswire/ — Originally prescribed by physicians across America for the treatment of type 2 diabetes, the prescription drug Actos (pioglitazone) was pulled from the market in June 2011 when the US Food and Drug Administration found that, when used for over twelve months, Actos may increase the risk of bladder cancer, report the Drug Litigation Attorneys at Eberstein & Witherite. Shortly after the drug reappeared on the market draped with a new cancer warning on the label.
This September, the FDA launched another safety review of Actos, shares Texas Actos lawyers Eberstein & Witherite. This review follows a French study that suggests patients taking Actos have an increased risk of bladder cancer. Based on this study, France has suspended use of the drug and limited its prescriptions to new diabetes patients. Drug Litigation Attorneys warn anyone who has or is currently taking Actos to consider the risks associated with the drug.
If you or a loved one has ever taken Actos for diabetes and are now exhibiting signs of bladder cancer, contact a doctor immediately. Early bladder cancer symptoms to watch for include pain during urination, frequent urinary tract infections, and only being able to urinate in small amounts. One of the most common signs of bladder cancer, occurring in 80-90% of infected individuals, is blood or blood clots in the urine, also known as Hematuria. Early detection of cancer is key in the fight to overcome it.
If you have bladder cancer and have taken Actos – call us. The Drug Litigation Attorneys http://www.productliabilitylawyerfirm.com/ at Eberstein & Witherite are available to answer questions about your rights and the next steps in Texas drug litigation against the distributor of this dangerous drug.
Visit or call 214-378-6665 today to start working with Actos Attorneys at Eberstein & Witherite.
SOURCE Eberstein & Witherite